Onyx Biotec Limited (NSE:ONYX)
India · Delayed Price · Currency is INR 37.25
+0.20 (0.54%)
At close: Oct 16, 2026
Onyx Biotec Revenue
In the fiscal year ending March 31, 2026, Onyx Biotec had annual revenue of 694.69M INR with 12.13% growth. Onyx Biotec had revenue of 348.84M in the half year ending March 31, 2026, with 16.83% growth. That makes Onyx Biotec the 38,586th largest company in the world by revenue and 3,505th in India.
Revenue
694.69M
Revenue Growth
+12.13%
P/S Ratio
0.97
Revenue / Employee
1.77M
Employees
393
Market Cap
675.42M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 694.69M | 75.16M | 12.13% |
| Mar 31, 2025 | 619.54M | 82.05M | 15.27% |
| Mar 31, 2024 | 537.49M | 142.57M | 36.10% |
| Mar 31, 2023 | 394.92M | -53.70M | -11.97% |
| Mar 31, 2022 | 448.61M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Mangalam Drugs & Organics | 2.32B |
| Concord Drugs | 860.69M |
| Source Natural Foods and Herbal Supplements | 796.24M |
| Mercury Laboratories | 737.65M |
| Shelter Pharma | 731.34M |
| Phaarmasia | 486.17M |
| Amwill Health Care | 454.92M |
| Biofil Chemicals and Pharmaceuticals | 346.26M |